Project Grant R01CA307311
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $734K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Beckman Research Institute of the City of Hope a $702,495 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2030. This research initiative focuses on developing novel therapeutic approaches to treat T cell lymphomas (TCLs), a highly heterogeneous group of lymphoid malignancies representing approximately 12% of all non-Hodgkin lymphomas. The project...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Project Grant Award Summary The University of California, San Francisco received a $677,787 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 26, 2025, with a completion date of July 31, 2030. The award funds research to identify and characterize Aire-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion and to develop therapeutic strategies targeting this...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Grant Award Summary The National Cancer Institute awarded University of California, Irvine a $648,626 Project Grant on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI). The research, which runs through March 31, 2031, addresses a critical gap in cancer immunotherapy by examining why PD-1 (programmed death receptor 1) blockade and dual checkpoint inhibitor...
- Federal Grant Award Summary The National Cancer Institute awarded a $663,340 Project Grant to the University of California, Berkeley on August 27, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The research will elucidate mechanisms by which local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer (NK) cells and CD4 T cells to control tumors that have...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $418,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) to advance programmable nucleic acid cytometry technology for isolating and analyzing rare cell populations from tumors and tissues. The three-year project, initiated September 1, 2025 and concluding August 31, 2028, focuses on continued development and validation of Programmable Enrichment via RNA...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period of May 1, 2026 through April 30, 2028. This award supports fundamental research investigating the innate and adaptive determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T-cell therapy. The research aims to elucidate the molecular mechanisms underlying...